(Reuters) - NEW YORK, April 19 - Wyeth said on Thursday quarterly earnings rose a better-than-expected 12 percent on strong sales of its vaccine against childhood infections, and reported positive trial results for its most important experimental drug.
The trial data shows low doses of Pristiq were effective against both depression and hot flashes and caused less nausea than seen in prior studies of higher doses. Although the new data will take more time for regulators to analyze, it could bolster prospects for its eventual approval and commercial success. Pristiq is now awaiting U.S. approval as a treatment for both conditions. But Wyeth and investors have been concerned about a high incidence of nausea seen among patients who took the drug in earlier trials to treat depression and hot flashes.
Read more at Reuters.com Market News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment